Product Pipeline


Inotek is developing therapies to treat serious eye diseases based on pioneering research on the protective effects of the naturally-occurring molecule adenosine.

Our product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation as well as a fixed-dose combination (FDC) that includes trabodenoson plus latanoprost, one of the leading current treatments for glaucoma.

We are also evaluating the potential of trabodenoson to directly target optic neuropathies.

Learn more about trabodenoson

Learn more about FDC


Trabodenoson is an investigational compound and is not yet approved by the FDA.